Suven Life bags 2 patents

Hyderabad-based Suven Life Sciences Limited has said two of its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases had been granted patents in Australia and New Zealand. The patents are valid up to 2022.

The granted claims of these patents include the class of selective 5-HT compounds discovered by the company.

These compounds are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's, attention deficient hyperactivity, Huntington's, Parkinson and Schizophrenia.

Thus far, Suven Life has filed 25 product patents under the Patent Cooperation Treaty (PCT), of which 10 have entered the national phase.